Objective
to report the 2-year clinical outcomes of implantation of Absorb BV Scaffold compared to Xience EES
Study
single-blind multicentre non-inferiority (1:1) randomised clinical trial (margin 3.3%)
Population
patients undergoing PCI and lesion suitable for either BVS or EES implantation
Endpoints
TVF as a composite cardiac death, MI and target vessel revascularisation at 2 years
Conclusion
At 2 years there is no statistically difference in target vessel failure between Absorb BVS and Xience EES. The thrombosis rate is higher with Absorb BVS
Tyssen et al. EuroIntervention. 2018;14:e426-33
